阿替利珠单抗在三阴性乳腺癌中的Meta分析

Atezolizumab in Triple Negative Breast Cancer:A Meta-analysis

目的系统评价服用阿替利珠单抗对三阴性乳腺癌的治疗疗效。方法检索中国知网、万方、PubMed,Clinicaltrials.gov数据库及SABCS、ESMO会议报道。检索时间自建库起至2022年2月15日。使用ReviewManager5.4.1进行Meta分析。结果共纳入5篇文献。与辅助治疗联用时,客观缓解率ORR=1.21、总生存率OS=2.60明显改善;与新辅助化疗联用时,pCR未见明显改善。结论阿替利珠单抗联合化疗能够改善患者的ORR及OS,但应当严格按照Impassion130标准选择患者。

Objective To systematically evaluate the efficacy of Atezolizumab in the treatment of triple-negative breast cancer.Methods CNKI,Wanfang,PubMed,ClinicalTrials.gov,SABCS,ESMO conference reports were retrieved.Retrieval time from database construction to February 15,2022.Meta-analysis was performed using ReviewManager5.4.1.Results A total of 5 literatures were included.When combined with adjuvant therapy,the objective response rate(ORR=1.21)and overall survival rate(OS-2.60)were significantly improved.There was no significant improvement in pCR when combined with neoadjuvant chemotherapy.Conclusion Atezolizumab combined with chemotherapy can improve ORR and OS in patients,but patients should be selected strictly according to Impassion130 criteria.